<DOC>
	<DOC>NCT01676701</DOC>
	<brief_summary>The purpose of this study is to evaluate the serum concentration of tabalumab after the administration using either prefilled syringe or auto-injector after the initial loading dose and after 12 weeks of treatment. Treatment period is followed by 40 weeks optional safety extension.</brief_summary>
	<brief_title>Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Ambulatory males or females â‰¥18 years of age Diagnosis of adultonset RA Active RA (at least 8/68 tender and at least 8/66 swollen joints) Screening Creactive protein &gt;1.2 times the upper limit of normal (ULN) or a screening erythrocyte sedimentation rate (ESR) &gt;28 millimeters per hour (mm/hr) Documented history of, or current, positive rheumatoid factor (RF) and/or anticyclic citrullinated peptide antibody (antiCCP Ab) test Regular use of methotrexate (MTX) for at least 12 weeks and stable dose (10 to 25 mg/week) for at least 8 weeks prior to baseline American College of Rheumatology (ACR) functional class I, II, or III Able and willing to inject tabalumab by themselves (or have an assistant who will inject tabalumab) and able and willing to complete all study procedures Able and willing to have blood drawn for pharmacokinetic (PK) sampling Use of oral corticosteroids at average daily doses of &gt;10 mg/day of prednisone or its equivalent within 6 weeks prior to baseline Injection of any parenteral (including intraarticular) corticosteroid within 6 weeks of baseline Have previously discontinued treatment with a biologic diseasemodifying antirheumatic drug (DMARD) or a novel drug that interrupts cytokine signaling (eg, Janus kinase [JAK] inhibitors) due to insufficient efficacy Participants who had discontinued biologic DMARDS for reasons other than efficacy will not be excluded but must have done so prior to baseline Participants who discontinued a JAK inhibitor for lack of efficacy Participants who discontinued a JAK inhibitor for reasons other than efficacy will not be excluded, but must have done so prior to baseline for 21 days Previous severe reaction to any biologic therapy that, in the opinion of the Investigator, would pose an unacceptable risk to the participant if participating in the study Have had an inadequate response to treatment with 3 or more of the following DMARDs prescribed alone or in combination at approved doses for a minimum of 90 days: leflunomide, azathioprine, cyclosporine, and/or sulfasalazine Use of other DMARDs (eg, gold salts, cyclosporin, azathioprine, or any other immunosuppressives) other than MTX, hydroxychloroquine, chloroquine, or sulfasalazine, or the use of a JAK inhibitor in the 8 weeks prior to baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>